Manufacture of pharmaceutical preparations
PROPHYLIX PHARMA HOLDING AS
Operating profit
NOK −71,000
Equity
NOK 2.2m
Incorporated
2017
Share capital
NOK 609,000
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating costs | 71k | |
| Operating profit (EBIT) | −71k | |
| Net financial items | −17.2m | |
| Profit for the year | −17.4m |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 3.1m | |
| of which current assets | 105k | |
| Equity | 2.2m | |
| Total liabilities | 938k |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.